Department of Gynecology and Obstetrics, Nord Hospital, Assistance Publique des Hôpitaux de Marseille (AP-HM), Aix Marseille Université, Marseille, France.
Department of Gynecology, Nice Teaching Hospital, Nice, France.
PLoS One. 2020 Oct 5;15(10):e0239476. doi: 10.1371/journal.pone.0239476. eCollection 2020.
Congenital heart diseases (CHDs) are the most common congenital malformations. The objective of our study was to evaluate the prenatal screening accuracy of congenital heart disease (CHD) in Southern France and to evaluate the impact of a prenatal diagnosis on pregnancies outcomes and neonatal outcomes. We performed a bicentric, retrospective observational study in the southern region over 4 years was conducted between 1 January 2014 and 31 December 2017. All foetuses and children under one year of age with CHD monitored in the UTHs (University Teaching Hospitals) in Marseille and Nice were included. CHD cases were divided into 3 groups: group 1, those with no possible options for anatomical repair; group 2, those with anatomical repair possibilities but that may require neonatal cardiologic management; and group 3, those with anatomical repair possibilities that do not require an emergency neonatal procedure. Among the 249070 deliveries during the study period, 677 CHD cases were included in the study. The overall prenatal screening rate was 71.5%. The screening rates were 97.8%, 63.6%, and 65.9% for groups 1, 2 and 3, respectively. Among group 2 CHD cases, 80% of the transpositions of the great arteries, 56% of the aortic coarctations, and 20% of the total anomalous pulmonary venous returns were detected during the prenatal period. A genetic anomaly was found in 16% of CHD cases. The overall mortality rate was 11.3% with a higher death rate in cases of prenatal screening (17.2% versus 2.1%; p < 0.001). However, when focusing only on children who died of CHD, prenatal screening did not create an impact (56.6% versus 100%, p = 0,140). Our data showed that the prenatal screening rate of CHD appears satisfactory in Southern France. Nevertheless, it could be improved for some CHD. This study did not find any benefit in terms of mortality from prenatal screening for CHD.
先天性心脏病(CHD)是最常见的先天性畸形。我们的研究目的是评估法国南部先天性心脏病(CHD)的产前筛查准确性,并评估产前诊断对妊娠结局和新生儿结局的影响。我们在马赛和尼斯的两所教学医院(UTHs)进行了一项为期 4 年的回顾性观察性研究,研究时间为 2014 年 1 月 1 日至 2017 年 12 月 31 日。所有在马赛和尼斯的 UTHs 监测的患有 CHD 的胎儿和一岁以下儿童均被纳入研究。CHD 病例分为 3 组:组 1,无解剖修复可能的病例;组 2,有解剖修复可能但可能需要新生儿心脏病学管理的病例;组 3,有解剖修复可能但不需要紧急新生儿手术的病例。在研究期间的 249070 次分娩中,有 677 例 CHD 病例被纳入研究。总的产前筛查率为 71.5%。组 1、组 2 和组 3 的筛查率分别为 97.8%、63.6%和 65.9%。在组 2 的 CHD 病例中,大动脉转位的 80%、主动脉缩窄的 56%和总肺静脉异常回流的 20%在产前得到了诊断。CHD 病例中有 16%存在遗传异常。总的死亡率为 11.3%,产前筛查组的死亡率更高(17.2%比 2.1%;p<0.001)。然而,当只关注死于 CHD 的儿童时,产前筛查并没有产生影响(56.6%比 100%,p=0.140)。我们的数据表明,法国南部的 CHD 产前筛查率似乎令人满意。然而,对于某些 CHD,还可以进一步提高。本研究未发现产前筛查对 CHD 死亡率有任何益处。